POM-peptide hybrid against Alzheimer's Desease

Alzheimer's disease (AD) is the sixth leading cause of disability due to its high incidence and represents a huge health and social problem. AD, which culminates in cognitive decline, involves various pathological events, including accumulation in the brain of betaamyloid protein (Aβ) aggregates responsible for triggering oxidative stress, synaptic degeneration, and neuronal death. Furthermore, increasing evidence posits that AD pathogenesis involves strong interactions with immunological mechanisms in the brain and microglia activation. Despite the current knowledge, the few drugs available can only mitigate symptoms without counteracting the multiple causes of AD. Within this scenario, a novel drug discovery paradigm, involving multifunctional agents able to interact with AD-relevant targets and compromised networks simultaneously will enable an effective therapeutic intervention.